BioDelivery Sciences (BDSI) and Endo (ENDP) Ink $180M Licensing and Development Agreement
BioDelivery Sciences International, a specialty pharmaceutical company focused on developing products in the areas of pain management and oncology supportive care, today announced it has signed a $180 million agreement with Endo Pharmaceuticals for worldwide exclusive rights to develop and commercialize BEMA Buprenorphine for the treatment of chronic pain. BEMA Buprenorphine utilizes BioDelivery Sciences’ patented BioErodible MucoAdhesive (BEMA) technology to deliver the pain-reliving opiate drug. Per the agreement, Endo will be responsible for the manufacturing, distribution, marketing and sales of BEMA Buprenorphine on a worldwide scale. Both companies will collaborate to organize the phase III clinical development program and regulatory…